Healthcare provider profile · identity verified

Fabio Spadaro, MD

Family Practice · EL PASO, TX · NPI 1093802894

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	374	118
Metformin Hcl	Metformin Hcl	298	93
Lisinopril	Lisinopril	240	74
Ozempic	Semaglutide	166	33
Losartan Potassium	Losartan Potassium	162	47
Amlodipine Besylate	Amlodipine Besylate	137	45
Hydrochlorothiazide	Hydrochlorothiazide	135	43
Simvastatin	Simvastatin	128	38
Rosuvastatin Calcium	Rosuvastatin Calcium	123	38
Levothyroxine Sodium	Levothyroxine Sodium	122	41
Tamsulosin Hcl	Tamsulosin Hcl	108	35
Trulicity	Dulaglutide	98	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	84	29
Celecoxib	Celecoxib	81	31
Omeprazole	Omeprazole	76	28
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	71	17
Duloxetine Hcl	Duloxetine Hcl	64	20
Gabapentin	Gabapentin	63	21
Metoprolol Succinate	Metoprolol Succinate	63	21
Pravastatin Sodium	Pravastatin Sodium	56	17
Jardiance	Empagliflozin	53	13
Fluticasone Propionate	Fluticasone Propionate	49	32
Famotidine	Famotidine	48	17
Trazodone Hcl	Trazodone Hcl	48	11
Glipizide	Glipizide	45	13
Metformin Hcl Er	Metformin Hcl	43	14
Alendronate Sodium	Alendronate Sodium	42	15
Triamcinolone Acetonide	Triamcinolone Acetonide	41	21
Carvedilol	Carvedilol	40	11
Montelukast Sodium	Montelukast Sodium	39	suppressed
Sertraline Hcl	Sertraline Hcl	38	12
Amitriptyline Hcl	Amitriptyline Hcl	36	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	33	11
Alprazolam	Alprazolam	32	suppressed
Topiramate	Topiramate	32	suppressed
Clopidogrel	Clopidogrel Bisulfate	31	11
Fluoxetine Hcl	Fluoxetine Hcl	30	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	25	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Memantine Hcl	Memantine Hcl	22	suppressed
Warfarin Sodium	Warfarin Sodium	22	suppressed
Atenolol	Atenolol	21	suppressed
Glimepiride	Glimepiride	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Baclofen	Baclofen	20	suppressed
Fenofibrate	Fenofibrate	18	suppressed
Lorazepam	Lorazepam	18	suppressed
Tresiba Flextouch U-100	Insulin Degludec	18	suppressed
Valsartan	Valsartan	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Naproxen	Naproxen	17	11
Farxiga	Dapagliflozin Propanediol	16	suppressed
Finasteride	Finasteride	16	suppressed
Humalog Kwikpen U-100	Insulin Lispro	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Allopurinol	Allopurinol	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Varenicline Tartrate	Varenicline Tartrate	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Eliquis	Apixaban	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Levemir Flexpen	Insulin Detemir	13	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Prednisone	Prednisone	12	11
Bupropion Hcl	Bupropion Hcl	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Potassium Chloride	Potassium Chloride	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Rybelsus	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error